Predictors of Mortality Among Patients With Head Trauma
Launched by AYMAN MAHMOUD ALSAYES · Apr 3, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well certain scoring systems can predict the chances of survival for patients who have suffered head injuries and are being treated in the intensive care unit (ICU). The researchers will evaluate scores like the Glasgow Coma Scale (which measures a person's level of consciousness), the Revised Trauma Score, and the APACHE II score, along with other factors such as age and lab results, to see how these can help in determining the risk of mortality for patients with traumatic brain injuries.
To participate in this trial, patients must be over 16 years old, have experienced a recent head injury, and have a Glasgow Coma Scale score lower than 15 when they arrive at the emergency department. However, those who have had a cardiac arrest, have a very low GCS score of 3, or have severe injuries to their spine, face, or chest, as well as those with pre-existing neurological disorders, will not be eligible. If someone qualifies, they can expect to undergo routine assessments related to their condition as part of the study, which aims to improve care for individuals with severe head trauma.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients with acute traumatic brain injury older than 16 years where presented in emergency department within 24 hours of trauma with a Glasgow coma scale less than 15
- Exclusion Criteria:
- • o Post cardiac arrest
- • Patients with GCS=3.
- • Patients with associated advanced cervical spine, maxillofacial, severe chest trauma.
- • Patients with previous neurological disorders
About Ayman Mahmoud Alsayes
Ayman Mahmoud Alsayes is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient outcomes, Mr. Alsayes oversees the design, implementation, and management of clinical trials across various therapeutic areas. His expertise in regulatory compliance and patient safety, combined with a strong collaborative network of healthcare professionals, ensures that trials are conducted with the highest standards of integrity and efficacy. Driven by a passion for improving healthcare solutions, Ayman Mahmoud Alsayes is committed to fostering scientific advancements that benefit both patients and the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported